ERα Biomodulator Inducing UPR Hyperactivation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current endocrine therapies for ERα positive breast and ovarian cancers are cytostatic, failing to kill dormant cancer cells, leading to recurrence and poor survival rates, with limited therapeutic options for resistant tumors.
Innovation Solution
Development of the compound (−)C-105, which binds to the estrogen receptor α (ERα) and induces hyperactivation of the unfolded protein response (UPR) in the endoplasmic reticulum, effectively killing ERα positive cancer cells, including those resistant to existing therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current endocrine therapies (tamoxifen, fulvestrant, aromatase inhibitors) are used to treat ERα positive breast cancer, then tumor growth is inhibited initially, but resistance develops and cells remain dormant leading to recurrence
Solution Approach 1:
The patent changes the mechanism of action from cytostatic (growth inhibition) to cytotoxic (cell death) by inducing the unfolded protein response. Compound C-105 binds to ERα and triggers UPR hyperactivation, leading to apoptosis of cancer cells including dormant ones, thereby transforming the therapeutic outcome from temporary growth control to durable cell elimination.
Solution Approach 2:
The patent converts the harmful effect of ERα mutations (which cause therapy resistance) into a beneficial target. Mutated ERα proteins that confer resistance to standard therapies are actually hyperactivated by C-105, leading to enhanced UPR activation and increased cell death in these previously resistant cells.
2Productivity
If cytostatic endocrine therapies are used, then tumor proliferation is blocked, but residual dormant cells survive and reactivate later
Solution Approach 1:
Instead of allowing dormant cells to remain quiescent (the conventional approach), the patent actively induces cell death in dormant cells through UPR hyperactivation. The therapy inverts the paradigm by making dormant cells vulnerable rather than protecting them, achieving complete eradication rather than mere growth inhibition.
Solution Approach 2:
The patent ensures continuous therapeutic action by eliminating all cancer cells including dormant ones, preventing future recurrence. The UPR induction mechanism provides sustained cell death signaling that continues until complete tumor eradication is achieved, rather than merely blocking proliferation temporarily.
3Reliability
If standard chemotherapy is used for resistant tumors, then some cell killing occurs, but multidrug resistance mechanisms (MDR1 overexpression) pump drugs out reducing effectiveness
Solution Approach 1:
The patent uses ERα as an intermediary target that is overexpressed in many cancers including resistant ones. By binding to ERα and inducing UPR, C-105 exploits this overexpression to deliver cytotoxic effects, turning the resistance mechanism (MDR1 pump) against the cell since the pump cannot efflux this UPR-inducing mechanism.
Solution Approach 2:
The patent changes the therapeutic parameter from direct cytotoxic chemotherapy (which can be pumped out) to UPR induction through ERα binding. This parameter change bypasses the MDR1 efflux mechanism entirely, as the mechanism of action occurs through intracellular signaling rather than direct drug accumulation that would be subject to pumping.
4Productivity
If existing therapies are used for ovarian cancer, then initial response is achieved, but tumors recur as resistant cancer after several cycles
Solution Approach 1:
The patent converts the harmful effect of cancer cell persistence (leading to recurrence) into a benefit by inducing complete cell death through UPR. Ovarian cancer cells that survive standard therapy and lead to recurrence are specifically targeted by C-105, which induces apoptosis in these persistent cells, thereby preventing recurrence.
Solution Approach 2:
Instead of accepting that some cells must remain dormant to avoid toxicity (the conventional trade-off), the patent inverts the approach by safely eliminating dormant cells through UPR induction. This inversion allows for complete tumor eradication without the need to tolerate persistent disease, extending disease-free survival.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
(−)C-105 demonstrates a significantly increased ability to kill breast cancer cells, including those with ERα mutations, leading to complete regression of tumors and long-term eradication of cancer cells, offering a superior therapeutic potential compared to existing endocrine therapies.
Implementation Method 1
induceshyperactivation of the unfolded protein response (UPR) in the endoplasmic reticulum
Data Source
AI summary
A set of small molecules ERα biomodulators that kill therapy-resistant ERα positive breast, ovarian, and endometrial cancer cells. These small molecules have increased therapeutic potential because of an increased ability to kill therapy-resistant breast cancer cells compared to BHPI and other conventional therapies (endocrine therapies, tamoxifen and fulvestrant/ICI). The new compounds do not only inhibit proliferation of the cancer cells but actually kills them, which prevents reactivation of tumors years later.